A single-center, randomized, controlled, 2-period cross-over, open-labelled trial to evaluate the impact of different application volumes on pharmacokinetic and pharmacodynamic properties of insulin aspart in subjects with type 1 diabetes.

Trial Profile

A single-center, randomized, controlled, 2-period cross-over, open-labelled trial to evaluate the impact of different application volumes on pharmacokinetic and pharmacodynamic properties of insulin aspart in subjects with type 1 diabetes.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2016

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Acronyms SPRINK-01
  • Most Recent Events

    • 20 Jul 2011 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health).
    • 20 Jul 2011 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
    • 17 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top